Skip to main content
Funded Studies

Michael W. Lark, PhD

Chief Scientific Officer and Senior Vice President of Research at Trevena, Inc.

Location: King of Prussia, PA United States

Dr. Lark is currently chief scientific officer at a clinical stage biotechnology company focused on the discovery and development of biased GPCR ligands. Dr. Lark manages the drug discovery and pre-clinical development portfolio. Prior to joining Trevena, he was vice president of biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers. He was previously director of musculoskeletal diseases at GlaxoSmithKline and senior investigator at Merck Research laboratories. He has published over 115 peer reviewed papers, reviews and book chapters and is an inventor on several patents. Dr. Lark is currently PI on two NIH grants focused on characterization and development of GPCR biased ligands. Dr. Lark received his BS in microbiology from the Pennsylvania State University and his PhD in molecular biology and microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the department of pathology at The University of Washington.

Associated Grants

  • Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.